ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
After market 00:53:46 | |||
| 764 USD | +0.83% |
|
762.2 | -0.23% |
| 05-14 | Eli Lilly reaches settlement with spa selling Mounjaro, Zepbound knockoffs | RE |
| 05-14 | Argus Adjusts Price Target on Eli Lilly to $840 From $770 | MT |
ETFs positioned on Eli Lilly and Company
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.15% | 2,383 M€ | +12.78% | ||
| 1.11% | 34 M€ | +11.62% | - | |
| 1.09% | 375 M€ | +8.28% | ||
| 1.06% | 26 M€ | +20.72% | - | |
| 1.05% | 206 M€ | -.--% | ||
| 1.00% | 205 M€ | -.--% | ||
| 0.95% | 26 M€ | +16.85% | - | |
| 0.94% | 11 M€ | -6.03% | - | |
| 0.91% | 6 M€ | +17.98% | - | |
| 0.90% | 121 M€ | +7.29% | - | |
| 0.89% | 744 M€ | +8.55% | ||
| 0.89% | 8 M€ | +5.15% | - | |
| 0.87% | 1 M€ | +3.03% | - | |
| 0.84% | 224 M€ | +3.83% | - | |
| 0.84% | 26 M€ | +0.30% | - | |
| 0.84% | 24 M€ | +0.14% | - | |
| 0.83% | 50 M€ | +9.54% | ||
| 0.83% | 13 M€ | -.--% | - | |
| 0.83% | 4 M€ | -.--% | - | |
| 0.83% | 3 M€ | +15.16% | - | |
| 0.80% | 1,166 M€ | +0.26% | - | |
| 0.80% | 607 M€ | +0.05% | - | |
| 0.79% | 264 M€ | -.--% | - | |
| 0.79% | 187 M€ | +9.40% | - | |
| 0.79% | 477 M€ | +11.58% |
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
764
USD
Average target price
850.4
USD
Spread / Average Target
+11.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.06% | 682B | |
| +30.35% | 586B | |
| -3.42% | 364B | |
| +18.02% | 327B | |
| +4.27% | 285B | |
| +15.53% | 240B | |
| +10.16% | 209B | |
| -8.14% | 203B | |
| +8.12% | 165B | |
| -1.42% | 161B |
- Stock Market
- Equities
- LLY Stock
- Funds and ETFs Eli Lilly and Company
